Clinical trial · Observational
Prognostic Value of KELIM Score and Inflammatory Markers in Ovarian Cancer
Integrative Prognostic Value of Inflammatory Markers and KELIM Score in Ovarian Cancer Patients Treated With Neoadjuvant Chemotherapy.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a retrospective observational study to evaluate the integrative prognostic value of inflammatory markers, specifically the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), alongside the CA-125 Elimination rate constant K (KELIM) score in advanced ovarian cancer patients. The study includes patients with advanced serous ovarian cancer (stage III or IV) who received neoadjuvant platinum-based chemotherapy followed by interval debulking surgery at Sohag University Hospital and Sohag Cancer Center between 2022 and 2025. The primary objective is to evaluate how well these biomarkers predict survival outcomes, including progression-free survival (PFS) and overall survival (OS). Additionally, the study aims to assess their significance in predicting the success of complete versus incomplete cytoreductive surgery following neoadjuvant chemotherapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Ovarian Cancer (Stage III or IV) After Neoadjuvant Chemotherapy | — | UNRESOLVED | — |
| High-grade Serous Ovarian Carcinoma | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Ovarian Cancer Cohort
- description
- Advanced serous ovarian cancer patients treated with neoadjuvant chemotherapy followed by interval debulking surgery.
Primary outcomes (2)
- measure
- Progression-Free Survival (PFS)
- timeFrame
- From the date of diagnosis up to 4 years (assessed using retrospective medical records of patients treated between 2022 and 2025).
- description
- Evaluation of the prognostic value of baseline neutrophil lymphocyte ratio, platelet lymphocyte ratio, and CA 125 KELIM score in predicting progression-free survival in locally advanced ovarian cancer patients receiving platinum-based neoadjuvant chemotherapy followed by interval debulking surgery. PFS is calculated as the time from the date of diagnosis to the date of first documented clinical or radiological disease progression, or death from any cause.
- measure
- Overall Survival (OS)
- timeFrame
- From the date of diagnosis up to 4 years (assessed using retrospective medical records of patients treated between 2022 and 2025).
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Female patients aged \\ge 18 years old., Histologically confirmed advanced epithelial ovarian cancer (High-Grade Serous Ovarian Carcinoma), Stage III or IV. Patients who received platinum-based neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) at Sohag University Hospital or Sohag Cancer Center between 2022 and 2025. Available complete medical records, including pre-treatment baseline CBC (for NLR and PLR calculation) and longitudinal CA-125 levels (for KELIM score estimation). Exclusion Criteria: Patients with non-epithelial ovarian tumors (e.g., germ cell tumors, sex cord-stromal tumors). Patients who underwent primary debulking surgery (PDS) before receiving chemotherapy. Patients with concurrent active malignancies or a history of other cancers within the past 5 years. Patients with active systemic inflammatory diseases, hematological disorders, or severe infections at baseline that could interfere with baseline inflammatory markers (NLR/PLR). Incomplete or missing clinical, surgical, or follow-up data. \-
References
Publications (2)
- BACKGROUNDPassos VF, Rodrigues LKA, Santiago SL. The effect of magnesium hydroxide-containing dentifrice using an extrinsic and intrinsic erosion cycling model. Arch Oral Biol. 2018 Feb;86:46-50. doi: 10.1016/j.archoralbio.2017.11.006. Epub 2017 Nov 14. PMID 29156417
- BACKGROUNDMadrigal-Valverde M, Bittencourt RF, Ribeiro Filho AD, Barbosa VF, Vieira CA, Romao EA, Carneiro IB, Azevedo MC, Araujo GR. Quality of domestic cat semen collected by urethral catheterization after the use of different alpha 2-adrenergic agonists. J Feline Med Surg. 2021 Aug;23(8):745-750. doi: 10.1177/1098612X20973183. Epub 2020 Nov 18. PMID 33206029